Kyverna Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	224.86	35.21	38.29	76.62
Short-Term Investments	145.51	22.9	13.59	0
Cash & Cash Equivalents	370.36	58.11	51.88	76.62
Cash Growth	613.94%	12.01%	-32.29%	-
Other Current Assets	5.12	2.56	1.38	0.47
Total Current Assets	375.49	60.66	53.25	77.09
Property, Plant & Equipment	12.75	10.61	12.44	7.81
Other Long-Term Assets	1.74	3.92	1.23	0.59
Total Long-Term Assets	14.5	14.53	13.67	8.4
Total Assets	389.98	75.2	66.92	85.49
Accounts Payable	7.45	4.36	1.45	0.77
Deferred Revenue	0	0	0	7.03
Current Debt	3.72	2.92	2.28	0.81
Other Current Liabilities	10.7	12.58	8.23	7.32
Total Current Liabilities	21.87	19.86	11.95	15.93
Long-Term Debt	7.13	6.16	8.29	4.74
Other Long-Term Liabilities	0	0	0.01	2.35
Total Long-Term Liabilities	7.13	6.16	8.29	7.09
Total Liabilities	28.99	26.02	20.25	23.02
Total Debt	10.85	9.08	10.56	5.56
Debt Growth	2.67%	-14.06%	90.17%	-
Retained Earnings	-162.74	-136.04	-75.68	-46.78
Comprehensive Income	-0	0	-0.03	0
Shareholders' Equity	360.99	-131.4	-74	-46.25
Net Cash / Debt	359.52	49.03	41.31	71.06
Net Cash / Debt Growth	770.25%	18.68%	-41.87%	-
Net Cash Per Share	-	72.78	90.70	267.27
Working Capital	353.62	40.81	41.3	61.16
Book Value Per Share	15.20	-195.06	-162.46	-173.96

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).